

Modified Form PTO-1449

Atty. Docket  
No. A-430F

Serial No. 09/907,263

## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant  
Bendele et al.Filing Date  
July 17, 2001RECEIVED  
1646

## U.S. PATENT DOCUMENTS

MAY 14 2003

EXAMINER'S INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
EA	A003	4,670,563	6/02/87	Jansen et al. (English equivalent of EP 0 169 112)		TECH CENTER	1600/2900
	A004	5,075,222	12/24/91	Hannum et al.			
	A005	5,093,475	3/3/92	Merrill			
	A006	5,344,915	9/06/94	LeMaire et al.			
	A007	5,466,823	11/14/95	Talley et al.			
	A008	5,563,165	10/8/96	Talley et al.			
	A009	5,605,690	02/25/97	Smith et al.			
	A010	5,691,374	11/25/97	Black et al.			
	A011	5,731,343	03/24/98	Feng et al.			
	A012	5,760,068	6/2/98	Talley et al.			
	A013	5,795,967	08/18/98	Aggarwal et al.			
	A014	5,958,409	9/28/99	Turk et al.			
	A015	5,972,986	10/26/99	Seibert et al.			
	A016	6,063,811	5/16/00	Hancock et al.			
✓	A017	6,096,728	8/01/00	Collins et al.			

File Copy

EXAMINER:

Eileen B. O'Hara

Date Considered:

7/23/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Modified Form PTO-1449

Atty. Docket  
No. A-430F

Serial No. 09/907,263

## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Bendele et al.

Filing Date

July 17, 2001

Group

RECEIVED

1646  
MAY 14 2003

## FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	TRANSLATION YES NO
EA	B003	WO 01/00229 A1	1/01	PCT		
	B004	WO 00/48583	08/24/00	PCT		
	B005	WO 98/16227	04/23/98	PCT		
	B006	WO 98/05357	02/12/98	PCT		
	B007	WO 96/26271	8/29/96	PCT		
	B008	WO 96/20729	07/11/96	PCT		
	B009	WO 96/19459 A1	06/27/96	PCT		
	B010	WO 94/06476	03/31/94	PCT		
	B011	WO 92/07585	05/14/92	PCT		
	B012	WO 92/01474 A1	2/06/92	PCT		
	B013	WO 90/14363	11/29/90	PCT		
	B014	WO 89/05145 A1	06/15/89	PCT		
	B015	EP 0 927 555	07/07/99	Europe		
	B016	EP 0 386 289 A1	9/12/90	Europe		
	B017	EP 0 247 860 A2	12/02/87	Europe		
	B018	EP 0 225 579 A3	6/16/87	Europe		
	B019	EP 0 169 112 B1	1/22/86	Europe (see U.S. 4,670,563 for English)		
	B020	EP 0 154 316 B1	9/11/85	Europe		
✓	B021	EP 0 154 316 A2	9/11/85	Europe		


EXAMINER:

Eileen B. O'Hara

Date Considered:

7/23/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Modified Form PTO-1449	Atty. Docket No. A-430F	Serial No. 09/907,263
<b>LIST OF REFERENCES CITED BY APPLICANT</b>  (Use several sheets if necessary)	Applicant Bendele et al.	<b>RECEIVED</b> MAY 14 2003 1646
	Filing Date July 17, 2001	

EXAMINER'S  
INITIALS**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

EMA	C004	Baker et al. (1992), "Inhibition of EAE by TNF-Receptor Fusion Proteins", <i>J. Neuroimmunology</i> , 54(1-2):151 Abstract P16.01.
	C005	Bakouche et al. (1988), "Plasma Membrane-Associated Tumor Necrosis Factor, A Non-Integral Membrane Protein Possibly Bound to Its Own Receptor", <i>J. Immunol.</i> 140:1142-1147.
	C006	Banner et al. (1993), "Crystal Structure of the Soluble Human 55 KD TNF Receptor-Human TNF $\beta$ Complex: Implications for TNF Receptor Activation", <i>Cell</i> , 73:431-445.
	C007	Barrera et al. (1993), "Circulating Soluble Tumor Necrosis Factor Receptors, Interleukin-2 Receptors, Tumor Necrosis Factor Alpha, and Interleukin-6 Levels in Rheumatoid Arthritis. Longitudinal Evaluation During Methotrexate and Azathioprine Therapy", <i>Arthritis and Rheumatism</i> 36(8):1070-1089.
	C008	Barrera et al. (1996), "Effects of Antirheumatic Agents on Cytokines", <i>Seminars in Arthritis and Rheumatism</i> , 25(4):234-253.
	C009	Bevilacqua et al. (1986), "Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: Characterization and comparison with the actions of interleukin 1", <i>Proc. Natl. Acad. Sci. USA</i> , 83:4533-4537.
	C010	Bologna et al. (1996), "Association Destraitements de Fond Dans La Polyarthrite Rhumatoide", <i>Presse Medicale</i> 25(19):876-878.
	C011	Borigini et al. (1995), "Combination Therapy," <i>Bailliere's Clin. Rheuma.</i> 9(4):689-710.
	C012	Brakebusch et al. (1993), "Diverse Functions of the Tumor Necrosis Factor Receptors: Structure-Activity Considerations", <i>Tumor Necrosis Factor: Molecular and Cellular Biology and Clinical Relevance</i> , Fiers W. Buurman WA (eds.) Basel. Karger, pgs. 40-51.
	C013	Braun et al. (2000), "Anti-TNF-alpha: A New Dimension in the Pharmacotherapy of the Spondyloarthropathies?," <i>Annals of the Rheumatic Diseases</i> 59(6):404-406.
	C014	Butler et al. (1994), "TNF Receptor Fusion Proteins Are Effective Inhibitors of TNF-Mediated Cytotoxicity On Human KYM-1D4 Rhabdomyosarcoma Cells," <i>Cytokine</i> , 6(6):616-623.
	C015	Capaldi et al. (1977), "Changes in Order of Migration of Polypeptides in Complex III and Cytochrome c Oxidase under Different Conditions of SDS Polyacrylamide Gel Electrophoresis," <i>Biochem. &amp; Biophys. Res Comm.</i> 74(2):425-433.
	C016	Carlino et al. (1987), "Use of a Sensitive Receptor Binding Assay to Discriminate Between Full-Length and Truncated Human Recombinant TNF Proteins", <i>J. Biol. Chem.</i> 262(3):958-961.
	C017	Carrieri et al. (1992), "Cytokines in the Pathogenesis of Multiple Sclerosis", <i>Acta Neurologica</i> , 14(4-6):333-341.
	C018	Chih-Hsueh Chen P. et al. (1995), "Mapping the Domain(s) Critical for the Binding of Human Tumor Necrosis Factor-Alpha to its Two Receptors", <i>The Journal of Biological Chemistry</i> , 270(6):2874-2878.

EXAMINER:

Eileen B. O'Hara

Date Considered:

7/23/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



RECEIVED

Sheet 4 Of MAY 14 2003

C019	Cronstein et al. (1994), "Adenosine Mediates the Antiinflammatory Effects of the Adenosine Kinase Inhibitor GP-1-515 in The Murine Air Pouch Model of Inflammation", <i>Arthritis &amp; Rheumatism</i> , 37(9):201.
C020	Delgado et al. (1992), "The Uses and Properties of PEG-Linked Proteins," <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> , 9(3,4):249-304.
C021	Dembic et al. (1990), "Two Human TNF Receptors Have Similar Extracellular, But Distinct Intracellular, Domain Sequences," <i>Cytokine</i> , 2(4):231-237.
C022	Dyson et al. (1990), "Influence of SK & F 95587 and BN 50730 on Bronchoconstrictor Responses in the Cat", <i>The Journal of Pharmacology and Experimental Therapeutics</i> , 255(3):1320-1327.
C023	Espevik et al. (1990), "Characterization of Binding and Biological Effects of Monoclonal Antibodies Against a Human Tumor Necrosis Factor Receptor", <i>Journal Exp. Med.</i> , 171:415-426.
C024	Evans, Ronald M. (1998), "The Steroid and Thyroid Hormone Receptor Superfamily," <i>Science</i> 240:889-895.
C025	Fu Z. -Q. (1995), "Model complexes of tumor necrosis factor-alpha with receptors R1 and R2", <i>Protein Engineering</i> , 8(12):1233-1241.
C026	Glass et al. (1979), "4-Phenoxy-3,5-Dinitrobenzoylpolyethyleneglycol: Reversible Attachment of Cysteine-Containing Polypeptides to Polymers in Aqueous Solutions", <i>Biopolymers</i> , 18:383-392.
C027	Hallenbeck & Frerichs (1993), "Stroke Therapy: It May Be Time For An Intergrated Approach", <i>Arch. Neurol.</i> 50:768-770.
C028	Hass et al. (1995), "Characterization of Specific High Affinity Receptors for Human Tumor Necrosis Factor on Mouse Fibroblasts," <i>J. Biol. Chem.</i> 260(22):12214-12218.
C029	Heller et al. (1990), "Amplified Expression of Tumor Necrosis Factor Receptor in Cells Transfected with Epstein-Barr Virus Shuttle Vector cDNA Libraries," <i>J. Biol. Chem.</i> , 265(10):5708-5717.
C030	Hilliquin et al. (1995), "Treatment of Rheumatoid Arthritis with Platelet Activating Factor Antagonist BN 50730", <i>The Journal of Rheumatology</i> , 22(9):1651-1654.
C031	Hilliquin et al. (1995), "Treatment of Carrageenan Induced Arthritis By The Platelet Activating Factor Antagonist BN 50730", <i>Annals of the Rheumatic Diseases</i> , 54:140-143.
C032	Hoes et al. (1995), "Optimization of Macromolecular Prodrugs of the Antitumor Antibiotic Adriamycin", <i>Journal of Controlled Release</i> , 2:205-213.
C033	Horner et al. (1983), "Aryl-vinylsulfone-reagentien Zum Schutz Und Nacheweis Von Thiofunktionen," <i>Phosphorus and Sulfur</i> 15:1-8.
C034	Israel et al. (1986), "Binding of Human TNF- $\alpha$ to High-Affinity Cell Surface Receptors: Effect of IFN," <i>Immunol. Lett.</i> 12:217-224.
C035	Jenkins et al. (1992), "Tumour Necrosis Factor Causes an Increase in Axonal Transport of Protein and Demyelination in the Mouse Optic Nerve", <i>Journal of Neurological Sciences</i> , 108:99-104.
C036	Kavanaugh et al. (1996), "Anti-TNF-alpha Monoclonal Antibody (MAB) Treatment of Rheumatoid Arthritis (RA) Patients with Active Disease on Methotrexate (MTX); Results of a Double-Blind, Placebo Controlled Multicenter Trial," <i>Arthritis &amp; Rheumatism</i> 39(9):S123.
C037	Kogan, Timothy (1992), "The Synthesis of Substituted Methoxy-Poly(EthyleneGlycol) Derivatives Suitable for Selective Protein Modification", <i>Synthetic Communications</i> , 22(16):2417-2424.

EXAMINER:

Date Considered:

7/23/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

OIP F JC109 3003  
MAY 07 2003  
PATENT TRADEMARK

Sheet 51-OF-FILED

MAY 14 2003

TECH CENTER 1600/2900

C038	Kumar et al. (1999), "Analgesic and Anti-Inflammatory Effects of Phosphodiesterase Inhibitors," <i>Indian Journal of Experimental Biology</i> 38(1):26-30.
C039	Liblau et al. (1992), "Tumor Necrosis Factor- $\alpha$ and Disease Progression in Multiple Sclerosis," <i>New Engl. J. Med.</i> 326(4):272-273.
C040	Marangonore et al. (1990), "Design and Characterization of Hirulogs: A Novel Class of Bivalent Peptide Inhibitors of Thrombin," <i>Biochemistry</i> , 29:7095-7101.
C041	Lorenz et al. (2000), "Biological Agents: A Novel Approach to the Therapy of Rheumatoid Arthritis," <i>Exp. Opin. Invest. Drugs</i> p. 1479-1490.
C042	Martin et al. (1995), "Inhibition of Tumor Necrosis Factor Is Protective Against Neurologic Dysfunction After Active Immunization of Lewis Rats with Myelin Basic Protein," <i>Exp. Neurol</i> , 131:221-228.
C043	McFarland, Henry (1995), "Therapeutic Approaches to Multiple Sclerosis," <i>J. Neurochem.</i> , 64(Suppl.):S73 (Abstract C).
C044	Miller-Blair et al. (1993), "Rheumatoid arthritis: New science, new treatment," <i>Geriatrics</i> , 48(6):28-38.
C045	Monastra et al. (1993), "Phosphatidylserine, a Putative Inhibitor of Tumor Necrosis Factor, Prevents Autoimmune Demyelination," <i>Neurology</i> , 43:153-163.
C046	Moreland et al. (1997), "Etanercept Therapy in Rheumatoid Arthritis," <i>Ann Intern Med.</i> 130(6):478-486.
C047	Moreland et al. (1999), "Treatment of Rheumatoid Arthritis With A Recombinant Human Tumor Necrosis Factor Receptor (p75)-Fc Fusion Protein," <i>N. England Journal of Medicine</i> 337(3):141-147.
C048	Neda, Hiroshi (1987), "Analysis of the Tumor Necrosis Factor (TNF) Receptor of Various Tumor Cells," <i>Sapporo Medical Journal</i> , 56(2):305-317 (Abstract in English, first page).
C049	Piguet et al. (1989), "Tumor Necrosis Factor/Cachectin Plays a Key Role in Bleomycin-Induced Pneumopathy and Fibrosis," <i>J. Exp. Med.</i> 170:655-663.
C050	Portoghese et al. (1986), "Opioid Agonist and Antagonist Bivalent Ligands. The Relationship Between Spacer Length and Selectivity at Multiple Opioid Receptors," <i>J. Med. Chem.</i> , 29:1855-1861.
C051	Powell et al. (1992), "The Role of Lymphotoxin and TNF in Demyelinating Diseases of the CNS," <i>Tumor Necrosis Factors: The Molecules and Their Emerging Role in Medicine</i> , ed. by B. Beutler; Raven Press, New York, pgs. 355-369.
C052	Powell et al. (1990), "Lymphotoxin and tumor necrosis factor-alpha production by myelin basic protein-specific T cell clones correlates with encephalitogenicity," <i>International Immunology</i> , 2(6): 539-544.
C053	Richardson et al. (1995), "New Therapies for Rheumatoid Arthritis," <i>Br. J. Clin. Pract.</i> 49(3):135-139.
C054	Ruddle et al. (1990), "An Antibody to Lymphotoxin and Tumor Necrosis Factor Prevents Transfer of Experimental Allergic Encephalomyelitis," <i>J. Exp. Med.</i> 172:1193-1200.
C055	Schacht (1993), "The Current and Future Therapy Strategies of Rheumatoid Arthritis," <i>Zeitschrift fur Rheumatologie</i> , 52:365-382.
C056	Scallon, et al. (1995), "Functional Comparisons of Different Tumor Necrosis Factor Receptor/IgG Fusion Proteins," <i>Cytokine</i> , 7(8): 759-770.
C057	Seitz et al. (1995), "Methotrexate Action in Rheumatoid Arthritis: Stimulation of Cytokine Inhibitor and Inhibition of Chemokine Production by Peripheral Blood Mononuclear Cells," <i>British Journal of Rheumatology</i> 34(7):602-609.

EXAMINER:

*Eileen B. O'Hara*

Date Considered:

*7/23/83*

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

OTPA 35709-5  
MAY 07 2003  
PATENT

RECEIVED  
Sheet 6 Of 6

C058	Seitz et al. (1996), "Interleukin 1 (IL-1) Receptor Antagonist, Soluble Tumor Necrosis Factor Receptors, IL-1 Beta, and IL-8--Markers of Remission in Rheumatoid Arthritis During Treatment With Methotrexate," <i>Journal of Rheumatology</i> 23(9):1512-1516.
C059	Selmaj et al. (1991), "Anti-Tumor Necrosis Factor Therapy Abrogates Autoimmune Demyelination," <i>Annals of Neurology by Am. Neurol. Assoc.</i> , 30(5):694-700.
C060	Selmaj et al. (1994), "Prevention of CHR-EAE with Soluble TNF Receptor P55 ", <i>J. Neuroimmunology</i> , 54(12):196, Abstract W15.05.
C061	Selmaj et al. (1995), "Prevention of Chronic Relapsing Experimental Autoimmune Encephalomyelitis by Soluble Tumor Necrosis Factor Receptor I", <i>J. Neuroimmunology</i> , 56:135-141.
C062	Selmaj et al. (1990), "Proliferation of Astrocytes In Vitro In Response to Cytokines: A Primary Role for Tumor Necrosis Factor," <i>J. Immunol.</i> 144(1):129-135.
C063	Selmaj et al. (1998), "Tumor Necrosis Factor Mediates Myelin and Oligodendrocyte Damage In Vitro," <i>Annals of Neurology</i> 23(4):339-346.
C064	Sharief et al. (1991), "Association Between Tumor Necrosis Factor-Alpha and Disease Progression in Patients With Multiple Sclerosis," <i>New England J of Med.</i> 325(7):467-472.
C065	Shimohigashi et al. (1982), "Dimeric Tetrapeptide Enkephalins Display Extraordinary Selectivity for the $\delta$ Opiate Receptor," <i>Nature</i> , 297:333-335.
C066	Simon et al. (2000), "New and Future Drug Therapies for Rheumatoid Arthritis," <i>Rheumatology</i> 39:36-42.
C067	Socher et al. (1987), "Antibodies against amino acids 1-15 of tumor necrosis factor block its binding cell-surface receptor," <i>Proc. Natl. Acad. Sci. USA</i> 84:8829-8833.
C068	Suffys et al. (1988), "Involvement of a Serine Protease in Tumour-Necrosis-Factor-Mediated Cytotoxicity," <i>Eur. J. Biochem.</i> 178:257-265.
C069	The Cytokine Factsbook, Callard (ed.), Academic Press Inc., San Diego, CA., pp. 244-246 (1994).
C070	Tracey et al. (1988), "Cachectin/Tumor Necrosis Factor Induces Cachexia, Anemia, and Inflammation," <i>J. Exp. Med.</i> 167:1211-1227.
C071	Unglaub et al. (1987), "Downregulation of Tumor Necrosis Factor (TNF) Sensitivity Via Modulation of TNF Binding Capacity by Protein Kinase C Activators," <i>J. Exp. Med.</i> 166:1788-1797.
C072	Weber et al. (1984), "Production of an Epidermal Growth Factor Receptor-Related Protein," <i>Science</i> 224:294-297.
C073	Weisman et al. (1990), "Soluble Human Complement Receptor Type I: In Vivo Inhibitor of Complement Suppressing Post-Ischemic Myocardial Inflammation and Necrosis", <i>Science</i> , 249:146-151).
C074	Zeigler, Elizabeth J. (1988), "Tumor Necrosis Factor in Humans," <i>New Engl. J. Med.</i> 318(23):1533-1535.

EXAMINER:

*Elisa B. O'Hara*

Date Considered:

*7/23/03*

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.